JP2017039702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017039702A5 JP2017039702A5 JP2016146928A JP2016146928A JP2017039702A5 JP 2017039702 A5 JP2017039702 A5 JP 2017039702A5 JP 2016146928 A JP2016146928 A JP 2016146928A JP 2016146928 A JP2016146928 A JP 2016146928A JP 2017039702 A5 JP2017039702 A5 JP 2017039702A5
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- crystalline form
- value
- resonance
- solid state
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001228 spectrum Methods 0.000 claims 12
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 7
- 238000001237 Raman spectrum Methods 0.000 claims 6
- 239000012458 free base Substances 0.000 claims 6
- 238000004319 19F solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 5
- 229950001290 Lorlatinib Drugs 0.000 claims 5
- IIXWYSCJSQVBQM-LLVKDONJSA-N OSP71S83EU Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 3
- 102100011141 ALK Human genes 0.000 claims 2
- 108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 102000027656 receptor tyrosine kinases Human genes 0.000 claims 2
- 108091007921 receptor tyrosine kinases Proteins 0.000 claims 2
- 230000000996 additive Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US62/199418 | 2015-07-31 | ||
| US201662352349P | 2016-06-20 | 2016-06-20 | |
| US62/352349 | 2016-06-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017039702A JP2017039702A (ja) | 2017-02-23 |
| JP2017039702A5 true JP2017039702A5 (hr) | 2017-04-06 |
| JP6218253B2 JP6218253B2 (ja) | 2017-10-25 |
Family
ID=56686850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016146928A Active JP6218253B2 (ja) | 2015-07-31 | 2016-07-27 | ロルラチニブ遊離塩基の結晶形態 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (hr) |
| EP (2) | EP3328867B9 (hr) |
| JP (1) | JP6218253B2 (hr) |
| KR (1) | KR102088188B1 (hr) |
| CN (3) | CN116063323A (hr) |
| AU (1) | AU2016304420B2 (hr) |
| BR (1) | BR112017028604A2 (hr) |
| CA (1) | CA2937257C (hr) |
| CY (1) | CY1123689T1 (hr) |
| DK (2) | DK3798222T3 (hr) |
| ES (2) | ES2842302T3 (hr) |
| FI (1) | FI3798222T3 (hr) |
| HK (1) | HK1252845A1 (hr) |
| HU (2) | HUE065536T2 (hr) |
| MX (2) | MX2021002220A (hr) |
| PL (2) | PL3328867T3 (hr) |
| PT (2) | PT3798222T (hr) |
| RU (1) | RU2018101363A (hr) |
| SG (1) | SG10201913200XA (hr) |
| SI (2) | SI3328867T1 (hr) |
| TW (1) | TWI616449B (hr) |
| WO (1) | WO2017021823A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017049383A1 (en) | 2015-09-24 | 2017-03-30 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| JP2020524701A (ja) * | 2017-06-22 | 2020-08-20 | サイクルニウム ファーマ インコーポレイテッド | ピリジン含有大環状化合物ライブラリーならびにその製造および使用方法 |
| HUE062926T2 (hu) * | 2017-10-10 | 2023-12-28 | Pfizer | Lorlatinib mint szabad bázis hidrátjának kristályos formája |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| WO2019209633A1 (en) | 2018-04-23 | 2019-10-31 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| MX2021008645A (es) * | 2019-01-17 | 2021-08-19 | Pfizer | Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk). |
| US20220289764A1 (en) * | 2019-07-18 | 2022-09-15 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| CN110530998A (zh) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| US20230117684A1 (en) | 2020-03-05 | 2023-04-20 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525476A (ja) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Ａｌｋ阻害剤としての複素環式誘導体 |
| WO2012121764A1 (en) | 2010-11-25 | 2012-09-13 | Ratiopharm Gmbh | Novel salts and polymorphic forms of afatinib |
| WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3013835B1 (en) | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| HUE062926T2 (hu) | 2017-10-10 | 2023-12-28 | Pfizer | Lorlatinib mint szabad bázis hidrátjának kristályos formája |
-
2016
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/ja active Active
- 2016-07-27 PT PT202023362T patent/PT3798222T/pt unknown
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/fi active
- 2016-07-27 PL PL16751665T patent/PL3328867T3/pl unknown
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/zh active Pending
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/zh active Pending
- 2016-07-27 TW TW105123769A patent/TWI616449B/zh active
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 SI SI201631027T patent/SI3328867T1/sl unknown
- 2016-07-27 HU HUE20202336A patent/HUE065536T2/hu unknown
- 2016-07-27 SI SI201631780T patent/SI3798222T1/sl unknown
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/pt not_active Application Discontinuation
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/ru unknown
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/pl unknown
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/da active
- 2016-07-27 ES ES16751665T patent/ES2842302T3/es active Active
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 ES ES20202336T patent/ES2972010T3/es active Active
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/zh active Pending
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/da active
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/ko active IP Right Grant
- 2016-07-27 PT PT167516657T patent/PT3328867T/pt unknown
- 2016-07-27 MX MX2021002220A patent/MX2021002220A/es unknown
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en active Application Filing
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/hu unknown
- 2016-07-27 MX MX2018001324A patent/MX2018001324A/es unknown
-
2018
- 2018-09-21 HK HK18112176.1A patent/HK1252845A1/zh unknown
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017039702A5 (hr) | ||
| JP2020536893A5 (hr) | ||
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| JP2015010091A5 (hr) | ||
| RU2020113141A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2014511840A5 (hr) | ||
| JP2011168587A5 (hr) | ||
| WO2012054364A3 (en) | Bicyclic diamines as janus kinase inhibitors | |
| MY150519A (en) | Imidazoquinolines with immuno-modulating properties | |
| JP2016065042A5 (hr) | ||
| NO20083059L (no) | Pyrimidinderivater | |
| NZ602271A (en) | Bicyclic compounds and their uses as dual c-src / jak inhibitors | |
| WO2009132202A3 (en) | Macrocyclic compounds and their use as kinase inhibitors | |
| JP2016537382A5 (hr) | ||
| RU2020102453A (ru) | Фармацевтические композиции | |
| RU2015103065A (ru) | Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения | |
| MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
| RU2009136593A (ru) | Кристаллические формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-(пиридин-2-ил)этенил]индазола, пригодные для лечения аномального роста клеток у илекопитаюших | |
| JP2013522325A5 (hr) | ||
| WO2017089390A8 (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
| JP2013520424A5 (hr) | ||
| MX2017012568A (es) | Cristal del compuesto alquinil benceno 3,5-disustituido. | |
| MX2014000635A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak. | |
| MY189352A (en) | Crystals of Azabicyclic Compound | |
| JP2016528242A5 (hr) |